Heart Valve Technology

This channel includes news and new device innovations about heart valve technologies, including the aortic valve, mitral valve, pulmonic valve, and tricuspid valve. This includes information on transcatheter valve technologies like transcatheter aortic valve replacement (TAVR, or implantation TAVI), transcatheter mitral valve replacement (TMVR), transcatheter and surgical valve repairs, ad surgical replacement valves.

COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019

October 3, 2019 – The three-year results from the...

The Boston Scientiofic Acurate Neo TAVR valve did not meet non-inferiority to the Sapien 3 valve in patients with severe aortic stenosis. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019

October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate...

The Portico FDA investigational device exemption (IDE) study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019

October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) study found that 30-day safety and...

Khaldoon Alaswad, M.D., right, director, cardiac catheterization lab, during a complex CTO procedure at Henry Ford Hospital.

Khaldoon Alaswad, M.D., right, director, cardiac catheterization lab, during a complex CTO procedure at Henry Ford Hospital. (Photo by Dave Fornell)

Feature | Henry Ford Hospital | October 01, 2019 | Dave Fornell, Editor

Henry Ford Hospital thought leaders...

This shows the TEE ultrasound imaging used to guide MitraClip procedures to treat functional mitral regurgitation.
360 Photos | 360 View Photos | October 02, 2019

This 360 degree view shows staff at the...

Videos | Cardiovascular Business | September 30, 2019

A discussion with Ruth Fisher, MBA, vice president of the...

Medtronic Launches Evolut Pro+ TAVR System
Technology | Heart Valve Technology | September 24, 2019

September 24, 2019 – Medtronic announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the...

Abbott Receives European CE Mark for Two Pediatric Heart Devices
News | Congenital Heart | September 20, 2019

September 20, 2019 – Abbott announced approvals in Europe for two of its pediatric devices — the Masters HP 15mm...

New Research on Tempo Temporary Pacing Lead to Be Featured at TCT 2019
News | Leads Implantable Devices | September 20, 2019

September 20, 2019 — BioTrace Medical Inc. announced the company’s key activities at the 31st annual...

Reducing Secondary Mitral Regurgitation in Heart Failure Does Not Improve Two-year Outcomes
News | Heart Valve Technology | September 11, 2019

September 11, 2019 — Percutaneous reduction of...

Abbott Launches Pivotal Trial of TriClip Tricuspid Valve Repair System
News | Heart Valve Technology | September 05, 2019

September 5, 2019 — Abbott announced the launch of the company's TRILUMINATE Pivotal trial evaluating the safety and...

The most popular cardiac technology news in August 2019 was the FDA clearance for a new indication for both the Edwards Sapien 3 and Medtronic CoreValve transcatheter aortic valve replacement (TAVR) devices for low-risk patients. This puts the technology on equal footing with the previous standard-of-care of open heart surgery, representing a paradigm shift in cardiology.

The most popular cardiac technology news in August 2019 was the FDA clearance for a new indication for both the Edwards Sapien 3 and Medtronic CoreValve transcatheter aortic valve replacement (TAVR) devices for low-risk patients. This puts the technology on equal footing with the previous standard-of-care of open heart surgery, representing a paradigm shift in cardiology. 

Feature | September 03, 2019 | Dave Fornell, Editor

September 3, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (...

Overlay Init